Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a shorter, stronger radiation course beat standard therapy for High-Risk prostate cancer?

NCT ID NCT02303327

Ongoing ⭐️ CURE ⭐️ Sponsor: Sir Mortimer B. Davis - Jewish General Hospital Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether a shorter course of higher-dose radiation can match or improve upon standard pelvic radiation plus a brachytherapy boost for men with high-risk prostate cancer. Participants also receive hormone therapy for 28 months. The study compares side effects and cancer control between the two approaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
radiation therapy (external beam radiation therapy and high-dose-rate brachytherapy boost) plus androgen deprivation therapy
What this could lead to
If one approach proves safer or more effective, it could become a new standard treatment for high-risk prostate cancer, potentially reducing side effects or improving cancer control.
What could go wrong
This is a phase 3 trial, but results may not show a clear advantage for either arm. Both treatments carry risks of urinary, bowel, and sexual side effects from radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH RISK ADENOCARCINOMA OF THE PROSTATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1, Canada

  • CHUM Notre-Dame

    Montreal, Quebec, H2L 4M1, Canada

  • CHUQ, L'Hôtel-Dieu de Québec

    Québec, Quebec, G1R 2J6, Canada

  • CHUS - Hôpital Fleurimont

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Centre Hospitalier des Vallées de l'Outaouais, Hôpital de Gatineau

    Gatineau, Quebec, J8P 7H2, Canada

  • Centre Hospitalier régional de Trois-Rivières

    Trois-Rivières, Quebec, G8Z 3R9, Canada

  • Centre de santé Rimouski-Neigette

    Rimouski, Quebec, G5L 5T1, Canada

  • Eastern Health

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • Jewish General Hospital, McGill University

    Montreal, Quebec, H3T 1E2, Canada

  • Lawson Health Research Institute

    London, Ontario, N6C 2R5, Canada

  • Montréal General Hospital

    Montreal, Quebec, H3G 1A4, Canada

  • Windsor Regional Hospital

    Windsor, Ontario, N8W2X3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.